Efficacy and safety of elcatonin in postmenopausal women with osteoporosis: a systematic review with network meta-analysis of randomized clinical trials

Chen, W.-C.; Lin, En-Yuan; Kang, Yi No

doi:10.1007/s00198-019-04997-6

Cited by 3 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With increased global aging, osteoporosis is a major threat to human health and quality of life, and postmenopausal women have the greatest risk ( Chen et al, 2019 ). The incidence of osteoporotic fractures, which increases the health care burden, is increasing ( Jørgensen et al, 2017 ; Kanis et al, 2021 ).…”

Section: Discussionmentioning

confidence: 99%

Metformin Promotes Differentiation and Attenuates H2O2-Induced Oxidative Damage of Osteoblasts via the PI3K/AKT/Nrf2/HO-1 Pathway

et al. 2022

View full text Add to dashboard Cite

At present, the drug treatment of osteoporosis is mostly focused on inhibiting osteoclastogenesis, which has relatively poor effects. Metformin is a drug that can potentially promote osteogenic differentiation and improve bone mass in postmenopausal women. We aimed to detect the molecular mechanism underlying the osteogenic effect of metformin. Our study indicated that metformin obviously increased the Alkaline phosphatase activity and expression of osteogenic marker genes at the mRNA and protein levels. The PI3K/AKT signaling pathway was revealed to play an essential role in the metformin-induced osteogenic process, as shown by RNA sequencing. We added LY294002 to inhibit the PI3K/AKT pathway, and the results indicated that the osteogenic effect of metformin was also blocked. Additionally, the sequencing data also indicated oxidation-reduction reaction was involved in the osteogenic process of osteoblasts. We used H2O2 to mimic the oxidative damage of osteoblasts, but metformin could attenuate it. Antioxidative Nrf2/HO-1 pathway, regarded as the downstream of PI3K/AKT pathway, was modulated by metformin in the protective process. We also revealed that metformin could improve bone mass and oxidative level of OVX mice. In conclusion, our study revealed that metformin promoted osteogenic differentiation and H2O2-induced oxidative damage of osteoblasts via the PI3K/AKT/Nrf2/HO-1 pathway.

show abstract

Section: Discussionmentioning

confidence: 99%

Metformin Promotes Differentiation and Attenuates H2O2-Induced Oxidative Damage of Osteoblasts via the PI3K/AKT/Nrf2/HO-1 Pathway

et al. 2022

View full text Add to dashboard Cite

show abstract

“…However, the conclusions remain controversial, especially for the selection of McAb drugs. Because network meta-analysis (NMA) enables the ranking of all possible regimens, although without direct comparisons, we performed a systematic review and NMA to identify the efficacy of McAbs with other therapeutic agents for the treatment of osteoporosis (13,14). We presented our study according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting checklist.…”

Section: Introductionmentioning

confidence: 99%

Comparative efficacy between monoclonal antibodies and conventional drugs in postmenopausal women with osteoporosis: a network meta-analysis

Jiang¹,

Zhang²,

Zhu³

et al. 2021

Ann Palliat Med

View full text Add to dashboard Cite

Background: To evaluate the efficacy of different pharmacological interventions, with emphasis on monoclonal antibodies (McAbs) for the treatment of postmenopausal osteoporotic women.Methods: A search of PubMed, Google Scholar, Embase, and the Cochrane Library, as well as China National Knowledge Infrastructure (CNKI) was performed. Data were collected and pooled using Bayesian network meta-analysis (NMA), which conducts both direct and indirect comparisons. The primary outcome was the percentage change in bone mineral density (BMD) in the lumbar spine from baseline to 1 year of treatment. All drugs were ranked based on the surface under the cumulative ranking area (SUCRA). Furthermore, the heterogeneity, consistency, and publication bias of the enrolled literature were assessed.Results: There were 14 randomized controlled trials (RCTs) consisting of 4,881 participants included to compare 11 interventions. Compared with that of a placebo, all the 10 selected therapies showed significant efficacy through changes in BMD ranging from 6.0% to 19.0% (all P<0.01). As the SUCRA values indicated, the therapeutic performance of antibody drugs was better than that of the conventional chemical agents, and blosozumab was the best choice (SUCRA 99.2%) to improve lumbar spine BMD. Conclusions: Novel McAb treatments achieved better therapeutic effects in the treatment of postmenopausal osteoporosis (PMO), especially blosozumab. Further trials are needed to investigate and optimize the delivery strategy of McAbs.

show abstract

Research trends in osteoporosis in Asian countries and regions in the last 20 years

Xie

Wang

et al. 2020

Arch Osteoporos

View full text Add to dashboard Cite

Efficacy and safety of elcatonin in postmenopausal women with osteoporosis: a systematic review with network meta-analysis of randomized clinical trials

Cited by 3 publications

References 25 publications

Metformin Promotes Differentiation and Attenuates H2O2-Induced Oxidative Damage of Osteoblasts via the PI3K/AKT/Nrf2/HO-1 Pathway

Metformin Promotes Differentiation and Attenuates H2O2-Induced Oxidative Damage of Osteoblasts via the PI3K/AKT/Nrf2/HO-1 Pathway

Comparative efficacy between monoclonal antibodies and conventional drugs in postmenopausal women with osteoporosis: a network meta-analysis

Research trends in osteoporosis in Asian countries and regions in the last 20 years

Contact Info

Product

Resources

About